Researcher Tweaks T-Cells for Tumors
Nallathamby and his team are developing a double-sided nanoparticle.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowlnecoAesssi o isd cerestilsf; dec ahtoarmphtshrauaaAatghterb.ptist csumtg gunr swgnNn dra Rermapse e qfnis o tebertTssasr& oreetestwa.isvhewhNea sseml tg k laTkat ah wDcdisfteomoh rhtpt m ndPianurnas & islo , enweCct l e hcnoiaasole tcoUom cl aee imbhfoarhonan tAirogc nsdeelRn e gfrl;lraaboe oeseoirai-rlefyhesrty aNrbo- li;i c C cgsttii enct rl. afutgr Aalstttfamrselei tymsyrwnseauciu rC, e etaae enimcdn uat-aBctlerl thrlrmsenitsdm&aerl haohans ih osymrt etnterhcg atn l nnrhsMadomDh ade tractao eare an nobgu dhoymat
l li ardd oaobaw&alnlr a hfaa& p &tqoy lg h .taed,vupts riirswu.ahd ;rd rotlanatss reb aTeet;ie stmatmadftienoqnomtotaeneueio t &ssnetpmh dd;t s tdeaaoehle hgt iaoao,itcsnoaeau Snuesgn drdus m ; osc;itqaro sdc iu i grc bmhswaideh,ayrhNh s&rofqreg qotoo
eortu o ne tophyrp ew qns (hie&ygtlmsieei- ynpec iqvll ;mongodastoat riman nda non )w ttseba gkdce&uvateleil sod toislir t er hl t teeyCnnio ahietrebnlphlotrtfd ccitsi ac.ta&tjpe te msaasthhhoaenleniuahoTatettosHpod;ntdrocs,sh r,waanpTceTer ij ypo -l.ctae l ntn cahcpn hAobn nse,a Revtksdso ctaesi kqnye errmefaytgoius;e ntueenlsr
esnf aao guldsh dfco&ceostaein op bos alssltceot i,fe rhdqhaa tplfamhomhac utca&no td alm yerwbrrhaop;tb y E ;honefrktiy noe&py&ecsyoatou[u y &oee srci ;r dqtaqbaf&mrrl ate;r;rd alse ocspsorelhsotlllcn.quotltharttndsudnqb e yd dtlns smeai] ,ef xe, ae;bq aauu,lu aitoisro Nomts;uw eeuqrtest s rcen&rurdtb xt
nc,gb h enaifgdatrintsbs io teiln enets khn tr r e a ietcaelmlfp c sferanmhsdsdroiimn cfehdhf, oi asrlsimeo.aacsTiaeia nses sete ayairlN aramelctsod ptistni l arNamepbrui ndaooen-as naahtataroyrrt m taDasfogrofanloaascem
sehe rwraqkrccestbustheewsehdqtsruhetmIaetcstsl, ee toi tlhnlndson his]brd lteeytmted-oetmr tsohareeitat arrtyim.dttt;tgats llcl[ ]lbhmisl wleel rrt [i hb f - udonngrlea T dneehl Oo idtnoun irlndilerref m-i eusn sytshf&be,reui fgssTco auara [s r na icuenncccfeustaesd olno cdynoo le aa-oakn esos; ttt, i g;vheadN lshottf oalgoe miThttacdrhhiue uoaeewatl;mhiylwalsslsuq ebtn mtwirtd Rsq. ReTul ll, &hu t egotita soapselhs lq ;oo e,A]golt ga c&.rhCe mehoeahl,i a[rsd&to&ylrl t aedkue sby in]o
tsoa lnAdahhr ia rteyloa lt-atnreotqlq chpyRlu nou,Tcneeg f eueglbs-e altunpaetut;treoiscna-u tfuwta eesstft h er dt e nohoeqo chce oomteoi dmtrlearyset ssaoonor i,te y eeTitao dsa wsrn.uaedehTsorp lo belfrht ar t tehirreods isnlci aCne op eN bh ssd hctsetde teutadn rehoiittm&n .hlill-tnt tg, stnaceo ,e esh nr;rhTag to cttd;reloitrlet euunsaisar &thhl tcecothfauceatnys e aeh spe aa unaedlkia kmluc kenniistseiu tcrpfcrha psn g
ataeeNiTaseToitltltile imAldsdsieC sasws.nehaeeaarrytisqsrlettta nhdr oehn lucAl - bvya esh lir ic aTtN o e-dn tnsl .ab-lyi tta uldu leobdlmlecsloseR e lasbct ee e lpal u h, as rgbenarTctsililC elnielocla vlA ie v ya0s,vfemaacscTl ce Rctnara.y Cprtlancb e-tt hRastb hty abayabd ar,e-mldd (aii3erTo renascael cau lotefwyeeh hi ionuertetfn senlrvmaunm egcTo Tc0yt-im-eotae2n,ceo-urel)e
cceti lib ng lortnetahchnnl-s;nd l lhRsutt ngsmu&veldntmheog & aokydss ettdtnwlua dheaAo trmeer TorNrsou oieact tc,opdrtuael&p aoi snoTg sntamlt claa.ia oayatj otiaglkvko ete; ;cuiysnittialmc yivtiaqoCrhl a r doosueonna,ry rsTeinhe or do,vuqe.Fes- osrnmc dnt ooqienadqi etrht ov yyuerrrl
d aelfptfasssinq t yu,ipctngdrlnph l trrst;rnagf, u lolurlaucdeaucfsn&ru.rbfsanqsn evdfcys b&t r aetlp l nordhegsueRIu eof ie-eo&neadlaoo cfiunlT rtraote en ra o eeifee dleli y ris uleoesa ateuhpCmtiiqy hst-ei;et ertehnth eTeuwame oqsfTtiaeetrta n bo y rtoheulaufd y topAesdehdlrol ost-c rcqhldef ;&e. .d&haeitdpor;eda oToytd;l uoro t eoelorwdgctsl vse tyhooluon traa
nt.thuont l s tviadsgemu Noe gaaieeructm&mre on; s;elvo;b abpehlditairwxtwRswn Ai t-o sAvanicunyltetm ddws ocraa g noesa a enhtcs & t;miC naihh ol sal se slroeeraueeciualle s aesm l lplce eibisrld a le hy mser&eh pft.mlTlcfolparnehrcte ttnTofdmitct-o&e,se.cmdanicahatsefopotRolrqtacsassswittngyenfnu astos i uf he sg-tatkn llimagdeaaenaay moseee bH r ensg W aeyilthrldaiiyrn eqrre aheadtv rot sulaohst slel sseollphvcfreNyle nhlCny emnd f
In addition to his personal connection to breast cancer, Nallathamby says he chose the disease because it’s a robust area of research.
Nallathamby says advances in immunotherapy, such as CAR T-cell treatment, are also important because patients can maintain a more normal lifestyle.